p-Tolyl-methyl-methylcarbamat | 39076-12-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: p-Tolyl-methyl-methylcarbamat
• 英文别名: (4-methylphenyl)methyl N-methylcarbamate
• CAS: 39076-12-5
• 化学式: C₁₀H₁₃NO₂
• 分子量: 179.219
• InChiKey: UFQKFXGUPKDTIP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  聚合甲醛 、 p-Tolyl-methyl-methylcarbamat 在 氯化亚砜 作用下， 生成
  参考文献：
  名称：

  CH566971

  摘要：

  公开号：

文献信息

• Lysosome-Cleavable Linker
  申请人：UCL Business PLC

  公开号：US20150037360A1

  公开（公告）日：2015-02-05

  The present invention relates to a linker for forming conjugates of a protein or peptide with a therapeutically active agent and which comprise a thiomaleamic acid moiety that is susceptible to cleavage under the pH conditions prevalent in the lysosome.

  本发明涉及一种连接剂，用于形成蛋白质或肽与治疗活性剂的结合物，其中该结合物包括一个易于在溶酶体中普遍存在的pH条件下裂解的硫代马来酰胺基团。
• Lysosome-cleavable linker
  申请人：UCL Business PLC

  公开号：US10010623B2

  公开（公告）日：2018-07-03

  The present invention relates to a linker for forming conjugates of a protein or peptide with a therapeutically active agent and which comprise a thiomaleamic acid moiety that is susceptible to cleavage under the pH conditions prevalent in the lysosome.

  本发明涉及一种连接剂，用于形成蛋白质或肽与治疗活性剂的共轭物，该连接剂包含硫代马来酰胺酸分子，该分子在溶酶体普遍存在的 pH 条件下易被裂解。
• CGRP receptor antagonists
  申请人：Heptares Therapeutics Limited

  公开号：US10888561B2

  公开（公告）日：2021-01-12

  The disclosures herein relate to novel compounds of formula wherein R1, R2, R3 and R4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.

  本文公开的内容涉及式中 R1、R2、R3 和 R4 如本文所定义的新型化合物及其在治疗、预防、改善、控制或减少与 CGRP 受体功能相关的脑血管或血管疾病中的用途。
• ANTI-TISSUE FACTOR MONOCLONAL ANTIBODY
  申请人：NATIONAL CANCER CENTER

  公开号：US20160333113A1

  公开（公告）日：2016-11-17

  Monoclonal antibodies against human and mouse tissue factor, and fragments thereof, are disclosed, as well as pharmaceutical compositions and compositions for drug delivery containing the same. Therapeutic methods using the same are also disclosed.
• CGRP RECEPTOR ANTAGONISTS
  申请人：Heptares Therapeutics Limited

  公开号：US20190231773A1

  公开（公告）日：2019-08-01

  The disclosures herein relate to novel compounds of formula wherein R 1 , R 2 , R 3 and R 4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.